- Home
- SNTI vs TACT Comparison
SNTI vs TACT Comparison
Compare SNTI & TACT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- TACT
- Stock Information
- Founded
- SNTI 2016
- TACT 1996
- Country
- SNTI United States
- TACT United States
- Employees
- SNTI N/A
- TACT N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- TACT Computer peripheral equipment
- Sector
- SNTI Health Care
- TACT Technology
- Exchange
- SNTI Nasdaq
- TACT Nasdaq
- Market Cap
- SNTI 53.6M
- TACT 46.1M
- IPO Year
- SNTI N/A
- TACT 1996
- Fundamental
- Price
- SNTI $2.05
- TACT $4.36
- Analyst Decision
- SNTI Strong Buy
- TACT Strong Buy
- Analyst Count
- SNTI 4
- TACT 1
- Target Price
- SNTI $8.75
- TACT $5.00
- AVG Volume (30 Days)
- SNTI 97.8K
- TACT 44.1K
- Earning Date
- SNTI 11-13-2025
- TACT 11-10-2025
- Dividend Yield
- SNTI N/A
- TACT N/A
- EPS Growth
- SNTI N/A
- TACT N/A
- EPS
- SNTI N/A
- TACT N/A
- Revenue
- SNTI N/A
- TACT $50,258,000.00
- Revenue This Year
- SNTI N/A
- TACT $21.67
- Revenue Next Year
- SNTI $150.00
- TACT $7.63
- P/E Ratio
- SNTI N/A
- TACT N/A
- Revenue Growth
- SNTI N/A
- TACT 8.27
- 52 Week Low
- SNTI $1.26
- TACT $3.12
- 52 Week High
- SNTI $16.94
- TACT $5.70
- Technical
- Relative Strength Index (RSI)
- SNTI 56.53
- TACT 49.47
- Support Level
- SNTI $1.44
- TACT $4.07
- Resistance Level
- SNTI $2.16
- TACT $4.54
- Average True Range (ATR)
- SNTI 0.18
- TACT 0.26
- MACD
- SNTI 0.02
- TACT 0.03
- Stochastic Oscillator
- SNTI 84.03
- TACT 64.57
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About TACT TransAct Technologies Incorporated
Transact Technologies Inc develops and sells software-driven technology and printing solutions. The company's software is sold under BOHA, AccuDate, Epic, EPICENTRAL, Ithaca, and Printrex brand names. It also provides supplies and consumables used in the printing and scanning activities to restaurant and hospitality, banking, retail, casino and gaming, point of sale automation, lottery, medical, mobile, oil, and gas markets. Majority of the revenue is derived from the casinos and gaming industry followed by the Foodservice technology market. Its geographical segments are the United States and International, of which the majority of its revenue comes from the United States.